by Julie Steenhuysen CHICAGO - A study of internal company documents suggests Pfizer Inc altered or omitted unfavorable study findings to expand its epilepsy drug Neurontin's market, U.S. researchers said on Wednesday, offering a look at how drugmakers influence scientific research. Clinical trials are supposed to answer a specific, predetermined scientific question, but a comparison of Pfizer ...

[News Source]